Scott Gottlieb, MD is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety. Dr. Gottlieb is an aggressive advocate for advancing the health of patients, promoting healthcare access, and driving innovation. The FDA’s prolific advances in new policy distinguished his tenure as commissioner, in addition to a record-setting number of approvals of novel drugs, medical devices, and generic medicines.
Previously, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services. He's worked as a venture capitalist and founder and board member to companies that developed new medicines and advance the delivery of healthcare. Dr. Gottlieb is widely published in leading medical journals and periodicals, including The Wall Street Journal, The New York Times, and The Washington Post. He has held editorial positions on the British Medical Journal and the Journal of the American Medical Association and appears regularly as a guest commentator on CNBC. He was a practicing hospitalist and a Clinical Assistant Professor at the New York University School of Medicine. Dr. Gottlieb is presently a Resident Fellow at AEI.